Bromadol BDPC, a recently synthetic pain reliever, has peculiar chemical characteristics. It mostly functions through the incomplete μ-opioid binding site agonist, also demonstrates considerable activity with a kappa-opioid binding site and also. This dual action results to a complex profile of consequences, such as pain reduction, drowsiness,